<DOC>
	<DOCNO>NCT00143247</DOCNO>
	<brief_summary>This long-term safety study Phase 2 subject choose remain Exubera® ( inhaled insulin ) .</brief_summary>
	<brief_title>Long-Term Safety Study Inhaled Insulin : An Up Four-Year Extension Therapy Subjects With Type 1 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The study terminate Oct. 18 , 2007 . This study post approval commitment study . Pfizer decide cancel new trial decision withdraw Exubera® ( inhaled insulin ) due lack market performance safety reason .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects Type 1 Type 2 Diabetes Mellitus participate previous Phase 2 extension protocol Smoking Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>